Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2937785 | 0.87 | LTB4R (0.66) | NR4A2MAOBSLC16A3LTB4RLTB4R2 | |
| SCHEMBL4419540 | 0.87 | MAOB (0.56) | NR4A2MAOBMAOASLC16A3LTB4R | |
| SCHEMBL4422282 | 0.84 | MAOB (0.78) | NR4A2MAOBMAOASLC16A3PPARA | |
| SCHEMBL6306287 | 0.84 | MAOB (0.65) | NR4A2MAOBMAOASLC16A3PPARA | |
| SCHEMBL4418983 | 0.84 | NR4A2 (0.54) | NR4A2MAOBMAOASLC16A3PPARA | |
| SCHEMBL3296065 | 0.83 | MAOB (0.76) | NR4A2MAOBMAOASLC16A3PPARA | |
| SCHEMBL10566317 | 0.81 | FFAR4 (0.52) | NR4A2MAOBMAOAPPARAFFAR1 | |
| SCHEMBL10397844 | 0.81 | MAOB (0.64) | NR4A2MAOBMAOASLC16A3PPARA | |
| SCHEMBL27608926 | 0.80 | NR4A2 (0.52) | NR4A2MAOBMAOASLC16A3LTB4R | |
| SCHEMBL7908630 | 0.80 | NR4A2 (0.60) | NR4A2MAOBMAOASLC16A3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| CN-1310890-C | Isoquinoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | CN | disclosed |
| CN-1649844-A | Isoquinoline derivatives | HOFFMANN LA ROCHE (CH) | 2005-08-03 | — | — | CN | disclosed |
| EP-1501804-A1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091219-A1 | ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | NR4A2 1590/4885MAOB 1/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.